Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2016 Mar 19

PMID 26987530

Citations 20

Authors

Mary Beth Terry

Jasmine A McDonald

Hui Chen Wu

Sybil Eng

Regina M Santella

Affiliations

Soon will be listed here.

Abstract

Epigenetic biomarkers, such as DNA methylation, can increase cancer risk through altering gene expression. The Cancer Genome Atlas (TCGA) Network has demonstrated breast cancer-specific DNA methylation signatures. DNA methylation signatures measured at the time of diagnosis may prove important for treatment options and in predicting disease-free and overall survival (tertiary prevention). DNA methylation measurement in cell free DNA may also be useful in improving early detection by measuring tumor DNA released into the blood (secondary prevention). Most evidence evaluating the use of DNA methylation markers in tertiary and secondary prevention efforts for breast cancer comes from studies that are cross-sectional or retrospective with limited corresponding epidemiologic data, raising concerns about temporality. Few prospective studies exist that are large enough to address whether DNA methylation markers add to the prediction of tertiary and secondary outcomes over and beyond standard clinical measures. Determining the role of epigenetic biomarkers in primary prevention can help in identifying modifiable pathways for targeting interventions and reducing disease incidence. The potential is great for DNA methylation markers to improve cancer outcomes across the prevention continuum. Large, prospective epidemiological studies will provide essential evidence of the overall utility of adding these markers to primary prevention efforts, screening, and clinical care.

Citing Articles

Early detection of breast cancer through the diagnosis of Nipple Aspirate Fluid (NAF).

Pant A, Anjankar A, Shende S, Dhok A, Jha R, Manglaram A Clin Proteomics. 2024; 21(1):45.

PMID: 38943056 PMC: 11212179. DOI: 10.1186/s12014-024-09495-4.

DNA Methylation-Based Diagnosis and Treatment of Breast Cancer.

Peng X, Zheng J, Liu T, Zhou Z, Song C, Zhang D Curr Cancer Drug Targets. 2024; 25(1):26-37.

PMID: 38441008 DOI: 10.2174/0115680096278978240204162353.

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.

Yin J, Gu T, Chaudhry N, Davidson N, Huang Y Front Immunol. 2024; 14:1325615.

PMID: 38268926 PMC: 10806158. DOI: 10.3389/fimmu.2023.1325615.

Expression and clinical significance of UBE2V1 in cervical cancer.

Ren Z, Liu Z, Ma S, Yue J, Yang J, Wang R Biochem Biophys Rep. 2021; 28:101108.

PMID: 34466666 PMC: 8385167. DOI: 10.1016/j.bbrep.2021.101108.

Prognostic and immunological value of in breast cancer: implications for SARS-CoV-2.

Wang J, Liu Y, Zhang S Aging (Albany NY). 2021; 13(13):16904-16921.

PMID: 34228637 PMC: 8312471. DOI: 10.18632/aging.203229.

References

Mensaert K, Denil S, Trooskens G, Van Criekinge W, Thas O, De Meyer T . Next-generation technologies and data analytical approaches for epigenomics. Environ Mol Mutagen. 2013; 55(3):155-70. DOI: 10.1002/em.21841. View

van Hoesel A, van de Velde C, Kuppen P, Putter H, de Kruijf E, van Nes J . Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res Treat. 2011; 131(3):859-69. DOI: 10.1007/s10549-011-1485-3. View

Wang W, Srivastava S . Strategic approach to validating methylated genes as biomarkers for breast cancer. Cancer Prev Res (Phila). 2010; 3(1):16-24. DOI: 10.1158/1940-6207.CAPR-09-0098. View

Muller H, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E . DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003; 63(22):7641-5. View

Mirza S, Sharma G, Parshad R, Srivastava A, Gupta S, Ralhan R . Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem. 2009; 43(4-5):380-6. DOI: 10.1016/j.clinbiochem.2009.11.016. View

Hoque M, Prencipe M, Poeta M, Barbano R, Valori V, Copetti M . Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2694-700. PMC: 4441328. DOI: 10.1158/1055-9965.EPI-08-0821. View

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Van der Auwera I, Elst H, Van Laere S, Maes H, Huget P, van Dam P . The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer. 2009; 100(8):1277-86. PMC: 2676551. DOI: 10.1038/sj.bjc.6605013. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

10.

Liggett T, Melnikov A, Marks J, Levenson V . Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer. 2010; 128(2):492-9. PMC: 2970661. DOI: 10.1002/ijc.25363. View

11.

Papadopoulou E, Davilas E, Sotiriou V, Georgakopoulos E, Georgakopoulou S, Koliopanos A . Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci. 2006; 1075:235-43. DOI: 10.1196/annals.1368.032. View

12.

Terry M, Delgado-Cruzata L, Vin-Raviv N, Wu H, Santella R . DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics. 2011; 6(7):828-37. PMC: 3154425. DOI: 10.4161/epi.6.7.16500. View

13.

Qaseem A, Snow V, Sherif K, Aronson M, Weiss K, Owens D . Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007; 146(7):511-5. DOI: 10.7326/0003-4819-146-7-200704030-00007. View

14.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

15.

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

16.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

17.

van Vlodrop I, Niessen H, Derks S, Baldewijns M, Van Criekinge W, Herman J . Analysis of promoter CpG island hypermethylation in cancer: location, location, location!. Clin Cancer Res. 2011; 17(13):4225-31. DOI: 10.1158/1078-0432.CCR-10-3394. View

18.

Balaghi M, Wagner C . DNA methylation in folate deficiency: use of CpG methylase. Biochem Biophys Res Commun. 1993; 193(3):1184-90. DOI: 10.1006/bbrc.1993.1750. View

19.

Sharma G, Mirza S, Parshad R, Srivastava A, Gupta S, Pandya P . Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biol. 2010; 32(1):23-32. DOI: 10.1007/s13277-010-0087-8. View

20.

Wu H, Delgado-Cruzata L, Flom J, Perrin M, Liao Y, Ferris J . Repetitive element DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry. Carcinogenesis. 2012; 33(10):1946-52. PMC: 3499042. DOI: 10.1093/carcin/bgs201. View